ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
ClearPoint Neuro, Inc. (NASDAQ: CLPT), a global device, cell, and gene therapy-enabling company focused on precise navigation to the brain and spine, has announced its plans to release financial results for the third quarter of 2024 on Thursday, November 7th, after market close. The company will host a live broadcast review of the Q3 2024 results on the same day at 4:30 p.m. Eastern time.
Investors and analysts can participate in the conference call via telephone or listen to the live broadcast online. For those unable to attend the live event, a replay will be available until December 7, 2024. An online archive of the broadcast will also be accessible on the company's Investor website.
ClearPoint Neuro, Inc. (NASDAQ: CLPT), un'azienda globale che sviluppa dispositivi, terapie cellulari e geniche focalizzata sulla navigazione precisa al cervello e alla colonna vertebrale, ha annunciato i suoi piani per pubblicare i risultati finanziari del terzo trimestre del 2024 il giovedì 7 novembre, dopo la chiusura del mercato. L'azienda ospiterà una diretta di revisione dei risultati del Q3 2024 lo stesso giorno alle 4:30 p.m. ora orientale.
Investitori e analisti possono partecipare alla teleconferenza tramite telefono o ascoltare la diretta online. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione fino al 7 dicembre 2024. Un archivio online della trasmissione sarà accessibile anche sul sito web degli investitori dell'azienda.
ClearPoint Neuro, Inc. (NASDAQ: CLPT), una empresa global dedicada a dispositivos, terapia celular y terapia génica enfocada en la navegación precisa hacia el cerebro y la columna vertebral, ha anunciado sus planes para publicar los resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre, después del cierre del mercado. La empresa llevará a cabo una revisión en directo de los resultados del Q3 2024 ese mismo día a las 4:30 p.m. hora del Este.
Los inversores y analistas pueden participar en la llamada de conferencia por teléfono o escuchar la transmisión en vivo en línea. Para aquellos que no puedan asistir al evento en vivo, se dispondrá de una repetición hasta el 7 de diciembre de 2024. También se podrá acceder a un archivo en línea de la transmisión en el sitio web de inversores de la empresa.
ClearPoint Neuro, Inc. (NASDAQ: CLPT), 뇌와 척수로의 정확한 내비게이션에 중점을 둔 글로벌 장치, 세포 및 유전자 치료 가능 회사가 2024년 3분기 재무 결과를 11월 7일 목요일, 시장 마감 후 발표할 계획을 발표했습니다. 회사는 같은 날 동일한 날 오후 4시 30분 동부 표준시에 3분기 2024 결과에 대한 실시간 방송 리뷰를 주최할 예정입니다.
투자자와 애널리스트는 전화로 컨퍼런스 콜에 참여하거나 온라인으로 실시간 방송을 들을 수 있습니다. 라이브 이벤트에 참석하지 못한 사람들을 위해 2024년 12월 7일까지 재생이 가능할 것입니다. 방송의 온라인 아카이브도 회사의 투자자 웹사이트에서 접근할 수 있습니다.
ClearPoint Neuro, Inc. (NASDAQ: CLPT), une entreprise mondiale spécialisée dans les dispositifs, les thérapies cellulaires et géniques axée sur la navigation précise vers le cerveau et la colonne vertébrale, a annoncé ses plans pour publier les résultats financiers du troisième trimestre 2024 le jeudi 7 novembre, après la clôture du marché. L'entreprise présentera le même jour à 16h30, heure de l'Est une révision en direct des résultats du Q3 2024.
Les investisseurs et analystes peuvent participer à la conférence téléphonique par téléphone ou écouter la diffusion en direct en ligne. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion sera disponible jusqu'au 7 décembre 2024. Une archive en ligne de la diffusion sera également accessible sur le site des investisseurs de l'entreprise.
ClearPoint Neuro, Inc. (NASDAQ: CLPT), ein weltweit tätiges Unternehmen, das sich auf Geräte, Zell- und Gentherapie zur präzisen Navigation zum Gehirn und zur Wirbelsäule konzentriert, hat seine Pläne zur Veröffentlichung der finanziellen Ergebnisse für das dritte Quartal 2024 am Donnerstag, den 7. November, nach Börsenschluss bekannt gegeben. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Live-Überprüfung der Q3 2024 Ergebnisse veranstalten.
Investoren und Analysten können an der Telefonkonferenz teilnehmen oder die Live-Übertragung online anhören. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung bis zum 7. Dezember 2024 verfügbar sein. Ein Online-Archiv der Übertragung wird ebenfalls auf der Investorenwebsite des Unternehmens zugänglich sein.
- None.
- None.
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close.
Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or at (862) 298-0702 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until December 7, 2024, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company’s Investor website at https://ir.clearpointneuro.com
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company’s products and services, the Company’s expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management’s current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s products and services; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their delivery of therapies; the Company’s ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2024, both of which have been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which the Company intends to file with the Security and Exchange Commission on or before November 14, 2024. The Company does not assume any obligation to update these forward-looking statements.
FAQ
When will ClearPoint Neuro (CLPT) release its Q3 2024 financial results?
What time is ClearPoint Neuro's (CLPT) Q3 2024 earnings call scheduled for?
How can investors participate in ClearPoint Neuro's (CLPT) Q3 2024 earnings call?
Until what date will the replay of ClearPoint Neuro's (CLPT) Q3 2024 earnings call be available?
